Current understanding and management of nasopharyngeal carcinoma

Auris Nasus Larynx

Volumn 39, Issue 2, 2012, Pages 137-144

  Yoshizaki, Tomokazu ^a   Ito, Makoto ^a   Murono, Shigekyuki ^a   Wakisaka, Naohiro ^a   Kondo, Satoru ^a   Endo, Kazuhira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Epstein Barr virus; LMP1; Molecular targeting therapy; Nasopharyngeal carcinoma; Radiotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; PROTEIN P16; PROTEIN P53; VIRUS ANTIBODY;

ANTIBODY TITER; ARCTIC; CANCER CHEMOTHERAPY; CHEMORADIOTHERAPY; CHINA; DISTANT METASTASIS; DOWN REGULATION; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; ETHNIC DIFFERENCE; GENE OVEREXPRESSION; GENE PRODUCT; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; JAPAN; METASTASIS; MIDDLE EAST; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; NORTH AFRICA; ONCOGENE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RACE DIFFERENCE; RADIATION DOSE; REVIEW; RISK FACTOR; SOUTHEAST ASIA; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRUS CARCINOGENESIS;

CELL TRANSFORMATION, NEOPLASTIC; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HERPESVIRUS 4, HUMAN; HUMANS; MOLECULAR TARGETED THERAPY; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; RADIOTHERAPY, INTENSITY-MODULATED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VIRAL MATRIX PROTEINS;

EID: 84856744853     PISSN: 03858146     EISSN: 18791476     Source Type: Journal    
DOI: 10.1016/j.anl.2011.02.012     Document Type: Review

References (89)

1. Cancer incidence in five continents, Vol. VIII 2002, IARC Scientific Publications No. 155. IARC. D.M. Parkin, S.L. Whelan, J. Ferlay, L. Teppo, D.B. Thomas (Eds.).
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Nielsen N.H., Mikkelsen F., Hansen J.P. Nasopharyngeal cancer in Greenland. The incidence in an Arctic Eskimo population. Acta Pathol Microbiol Scand A 1977, 85:850-858.
4. Dickson R.I., Flores A.D. Nasopharyngeal carcinoma: an evaluation of 134 patients treated between 1971-1980. Laryngoscope 1985, 95:276-283.
5. Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res 1974, 34:1189-1191.
6. Raab-Traub N., Flynn K., Pearson G., Huang A., Levine P., Lanier A., et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer 1987, 39:25-29.
7. Shanmugaratnam K. Histological typing of nasopharyngeal carcinoma. IARC Sci Publ 1978, 3-12.
8. Micheau C., Rilke F., Pilotti S. Proposal for a new histopathological classification of the carcinomas of the nasopharynx. Tumori 1978, 64:513-518.
9. Reddy S.P., Raslan W.F., Gooneratne S., Kathuria S., Marks J.E. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 1995, 16:103-108.
10. Marks J.E., Phillips J.L., Menck H.R. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998, 83:582-588.
11. Nicholls J.M. Nasopharyngeal carcinoma: classification and histological appearances. Adv Anat Pathol 1997, 4:71-84.
12. Pearson G.R., Weiland L.H., Neel H.B., Taylor W., Earle J., Mulroney S.E., et al. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 1983, 51:260-268.
13. Pathmanathan R., Prasad U., Sadler R., Flynn K., Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995, 333:693-698.
14. Chan A.S., To K.F., Lo K.W., Mak K.F., Pak W., Chiu B., et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 2000, 60:5365-5370.
15. Lo K.W., Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:451-462.
16. Murono S., Yoshizaki T., Tanaka S., Takeshita H., Park C.S., Furukawa M. Detection of Epstein-Barr virus in nasopharyngeal carcinoma by in situ hybridization and polymerase chain reaction. Laryngoscope 1997, 107:523-526.
17. Yoshizaki T., Endo K., Ren Q., Wakisaka N., Murono S., Kondo S., et al. Oncogenic role of Epstein-Barr virus-encoded small RNAs (EBERs) in nasopharyngeal carcinoma. Auris Nasus Larynx 2007, 34:73-78.
18. Yoshizaki T., Wakisaka N., Pagano J.S. Epstein-Barr virus, invasion and metastasis 2005, Caister Academic Press, 171-96.
19. Yoshizaki T., Sato H., Furukawa M., Pagano J.S. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci U S A 1998, 95:3621-3626.
20. Yoshizaki T., Sato H., Murono S., Pagano J.S., Furukawa M. Matrix metalloproteinase 9 is induced by the Epstein-Barr virus BZLF1 transactivator. Clin Exp Metastasis 1999, 17:431-436.
21. Yoshizaki T., Horikawa T., Qing-Chun R., Wakisaka N., Takeshita H., Sheen T.S., et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res 2001, 7:1946-1951.
22. Kondo S., Wakisaka N., Schell M.J., Horikawa T., Sheen T.S., Sato H., et al. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer 2005, 115:368-376.
23. Kondo S., Seo S.Y., Yoshizaki T., Wakisaka N., Furukawa M., Joab I., et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res 2006, 66:9870-9877.
24. Endo K., Kondo S., Shackleford J., Horikawa T., Kitagawa N., Yoshizaki T., et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene 2009, 28:1725-1735.
25. Kimura Y., Suzuki D., Tokunaga T., Takabayashi T., Yamada T., Wakisaka N., et al. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005. Auris Nasus Larynx 2010.
26. Gasco M., Crook T. The p53 network in head and neck cancer. Oral Oncol 2003, 39:222-231.
27. Chen M.K., Lee H.S., Chang J.H., Chang C.C. Expression of p53 protein and primary tumour volume in patients with nasopharyngeal carcinoma. J Otolaryngol 2004, 33:304-307.
28. Wu H.C., Lu T.Y., Lee J.J., Hwang J.K., Lin Y.J., Wang C.K., et al. MDM2 expression in EBV-infected nasopharyngeal carcinoma cells. Lab Invest 2004, 84:1547-1556.
29. Burgos J.S. Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis. Med Oncol 2005, 22:113-121.
30. Murono S., Yoshizaki T., Park C.S., Furukawa M. Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology 1999, 34:432-438.
31. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734.
32. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998, 2:305-316.
33. Crook T., Nicholls J.M., Brooks L., O'Nions J., Allday M.J. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?. Oncogene 2000, 19:3439-3444.
34. Potapova O., Gorospe M., Dougherty R.H., Dean N.M., Gaarde W.A., Holbrook N.J. Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 2000, 20:1713-1722.
35. Sheu L.F., Chen A., Lee H.S., Hsu H.Y., Yu D.S. Cooperative interactions among p53, bcl-2 and Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma cells. Pathol Int 2004, 54:475-485.
36. Shibosawa E., Tsutsumi K., Koizuka I., Hoshikawa M., Takakuwa T. Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas. Laryngoscope 2000, 110:93-97.
37. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
38. El-Naggar A.K., Lai S., Clayman G.L., Zhou J.H., Tucker S.A., Myers J., et al. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 1999, 30:1013-1018.
39. Gulley M.L., Nicholls J.M., Schneider B.G., Amin M.B., Ro J.Y., Geradts J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998, 152:865-869.
40. Reed A.L., Califano J., Cairns P., Westra W.H., Jones R.M., Koch W., et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996, 56:3630-3633.
41. Song X., Tao Y.G., Deng X.Y., Jin X., Tan Y.N., Tang M., et al. Heterodimer formation between c-Jun and Jun B proteins mediated by Epstein-Barr virus encoded latent membrane protein 1. Cell Signal 2004, 16:1153-1162.
42. Ohtani N., Brennan P., Gaubatz S., Sanij E., Hertzog P., Wolvetang E., et al. Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. J Cell Biol 2003, 162:173-183.
43. Rayman J.B., Takahashi Y., Indjeian V.B., Dannenberg J.H., Catchpole S., Watson R.J., et al. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev 2002, 16:933-947.
44. Hwang C.F., Cho C.L., Huang C.C., Wang J.S., Shih Y.L., Su C.Y., et al. Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol 2002, 13:1246-1251.
45. Makitie A.A., MacMillan C., Ho J., Shi W., Lee A., O'Sullivan B., et al. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res 2003, 9:2177-2184.
46. Wang G.L., Lo K.W., Tsang K.S., Chung N.Y., Tsang Y.S., Cheung S.T., et al. Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 1999, 81:1122-1126.
47. Tatsumi-Tamori A., Yoshizaki T., Miwa T., Furukawa M. Clinical evaluation of staging system for nasopharyngeal carcinoma: comparison of fourth and fifth editions of UICC TNM classification. Ann Otol Rhinol Laryngol 2000, 109:1125-1129.
48. Perez C.A., Devineni V.R., Marcial-Vega V., Marks J.E., Simpson J.R., Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 1992, 23:271-280.
49. Chang C.C., Chen M.K., Liu M.T., Wu H.K. The effect of primary tumor volumes in advanced T-staged nasopharyngeal tumors. Head Neck 2002, 24:940-946.
50. Sze W.M., Lee A.W., Yau T.K., Yeung R.M., Lau K.Y., Leung S.K., et al. Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. Int J Radiat Oncol Biol Phys 2004, 59:21-27.
51. Lo Y.M. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann N Y Acad Sci 2001, 945:68-72.
52. Lee A.W., Poon Y.F., Foo W., Law S.C., Cheung F.K., Chan D.K., et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992, 23:261-270.
53. Wang C.C. Improved local control of nasopharyngeal carcinoma after intracavitary brachytherapy boost. Am J Clin Oncol 1991, 14:5-8.
54. Kwong D.L., Sham J.S., Chua D.T., Choy D.T., Au G.K., Wu P.M. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1997, 39:703-710.
55. Lee A.W., Sham J.S., Poon Y.F., Ho J.H. Treatment of stage I nasopharyngeal carcinoma: analysis of the patterns of relapse and the results of withholding elective neck irradiation. Int J Radiat Oncol Biol Phys 1989, 17:1183-1190.
56. Kwong D., Sham J., Choy D. The effect of loco-regional control on distant metastatic dissemination in carcinoma of the nasopharynx: an analysis of 1301 patients. Int J Radiat Oncol Biol Phys 1994, 30:1029-1036.
57. Levendag P.C., Lagerwaard F.J., de Pan C., Noever I., van Nimwegen A., Wijers O., et al. High-dose, high-precision treatment options for boosting cancer of the nasopharynx. Radiother Oncol 2002, 63:67-74.
58. Le Q.T., Tate D., Koong A., Gibbs I.C., Chang S.D., Adler J.R., et al. Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003, 56:1046-1054.
59. Chua D.T., Sham J.S., Kwong P.W., Hung K.N., Leung L.H. Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications. Int J Radiat Oncol Biol Phys 2003, 56:177-183.
60. Waldron J., Tin M.M., Keller A., Lum C., Japp B., Sellmann S., et al. Limitation of conventional two dimensional radiation therapy planning in nasopharyngeal carcinoma. Radiother Oncol 2003, 68:153-161.
61. Cheng J.C., Chao K.S., Low D. Comparison of intensity modulated radiation therapy (IMRT) treatment techniques for nasopharyngeal carcinoma. Int J Cancer 2001, 96:126-131.
62. Hong R.L., Lin C.Y., Ting L.L., Ko J.Y., Hsu M.M. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA. Cancer 2004, 100:1429-1437.
63. Kwong D.L., Pow E.H., Sham J.S., McMillan A.S., Leung L.H., Leung W.K., et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 2004, 101:1584-1593.
64. Kwong D.L., Sham J.S., Leung L.H., Cheng A.C., Ng W.M., Kwong P.W., et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 64:374-381.
65. Kam M.K., Leung S.F., Zee B., Chau R.M., Suen J.J., Mo F., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25:4873-4879.
66. McMillan A.S., Pow E.H., Kwong D.L., Wong M.C., Sham J.S., Leung L.H., et al. Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: results of a prospective longitudinal study. Head Neck 2006, 28:712-722.
67. Lee N., Harris J., Garden A.S., Straube W., Glisson B., Xia P., et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009, 27:3684-3690.
68. Teo P.M., Leung T.W., Chan A.T., Yu P., Lee W.Y., Leung S.F., et al. A retrospective study of the use of cisplatinum-5-fluorouracil neoadjuvant chemotherapy in cervical-node-positive nasopharyngeal carcinoma (NPC). Eur J Cancer B Oral Oncol 1995, 31B:373-379.
69. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or =N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys. 1996;35:463-9.
70. Garden A.S., Lippman S.M., Morrison W.H., Glisson B.S., Ang K.K., Geara F., et al. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Int J Radiat Oncol Biol Phys 1996, 36:1005-1012.
71. Rossi A., Molinari R., Boracchi P., Del Vecchio M., Marubini E., Nava M., et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988, 6:1401-1410.
72. Chan A.T., Teo P.M., Leung T.W., Leung S.F., Lee W.Y., Yeo W., et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995, 33:569-577.
73. Al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper J., Vuong T., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
74. Chua D.T., Sham J.S., Choy D., Lorvidhaya V., Sumitsawan Y., Thongprasert S., et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998, 83:2270-2283.
75. Lee A.W., Lau W.H., Tung S.Y., Chua D.T., Chappell R., Xu L., et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005, 23:6966-6975.
76. Wee J., Tan E.H., Tai B.C., Wong H.B., Leong S.S., Tan T., et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005, 23:6730-6738.
77. Chen Y., Liu M.Z., Liang S.B., Zong J.F., Mao Y.P., Tang L.L., et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 2008, 71:1356-1364.
78. Kwong D.L., Sham J.S., Au G.K., Chua D.T., Kwong P.W., Cheng A.C., et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004, 22:2643-2653.
79. Chi K.H., Chang Y.C., Guo W.Y., Leung M.J., Shiau C.Y., Chen S.Y., et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002, 52:1238-1244.
80. Fuwa N., Shikama N., Hayashi N., Matsuzuka T., Toita T., Yuta A., et al. Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil--a phase II study. Oral Oncol 2007, 43:948-955.
81. Fang F.M., Chiu H.C., Kuo W.R., Wang C.J., Leung S.W., Chen H.C., et al. Health-related quality of life for nasopharyngeal carcinoma patients with cancer-free survival after treatment. Int J Radiat Oncol Biol Phys 2002, 53:959-968.
82. McMillan A.S., Pow E.H., Leung W.K., Wong M.C., Kwong D.L. Oral health-related quality of life in southern Chinese following radiotherapy for nasopharyngeal carcinoma. J Oral Rehabil 2004, 31:600-608.
83. Wei W.I., Ho C.M., Wong M.P., Ng W.F., Lau S.K., Lam K.H. Pathological basis of surgery in the management of postradiotherapy cervical metastasis in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1992, 118:923-929. discussion 30.
84. Khafif A., Ferlito A., Takes R.P., Robbins K.T. Is it necessary to perform radical neck dissection as a salvage procedure for persistent or recurrent neck disease after chemoradiotherapy in patients with nasopharyngeal cancer?. Eur Arch Otorhinolaryngol 2010, 267:997-999.
85. Yoshizaki T., Wakisaka N., Murono S., Shimizu Y., Furukawa M. Endoscopic nasopharyngectomy for patients with recurrent nasopharyngeal carcinoma at the primary site. Laryngoscope 2005, 115:1517-1519.
86. Chua D.T., Wei W.I., Sham J.S., Cheng A.C., Au G. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma. Head Neck 2003, 25:585-594.
87. Yoshizaki T., Wakisaka N., Kondo S., Murono S., Shimizu Y., Nakashima M., et al. Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J Med Virol 2008, 80:879-882.
88. Smith C., Wakisaka N., Crough T., Peet J., Yoshizaki T., Beagley L., et al. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood 2009, 113:6148-6152.
89. Khanna R., Moss D., Gandhi M. Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat Clin Pract Oncol 2005, 2:138-149.